SNGX Company Profile and Key Details
NASDAQ : SNGX
Soligenix
$0.94
0.4272+83.27%
Open: 2:34 PM64.48
BESG ScoreESG Rating
Price Chart
Stock Price Today
Soligenix, Inc. (SNGX) stock surged +83.27%, trading at $0.94 on NASDAQ, up from the previous close of $0.51. The stock opened at $0.99, fluctuating between $0.81 and $1.13 in the recent session.
Stock Snapshot
0.513
Prev. Close
9.69M
Market Cap
0.807
Day Low
-0.65
P/E Ratio
-1.45
EPS (TTM)
-0.83
Cash Flow per Share
0.99
Open
10.31M
Number of Shares
1.13
Day High
99.97%
Free Float in %
0.24
Book Value
230.08M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 26, 2026 | 0.40 | 0.54 | 0.39 | 0.51 | 62.78M |
| May 22, 2026 | 0.39 | 0.41 | 0.38 | 0.39 | 931.97K |
| May 21, 2026 | 0.38 | 0.40 | 0.35 | 0.39 | 739.5K |
| May 20, 2026 | 0.37 | 0.39 | 0.36 | 0.39 | 381K |
| May 19, 2026 | 0.40 | 0.40 | 0.35 | 0.38 | 816.81K |
| May 18, 2026 | 0.38 | 0.41 | 0.34 | 0.41 | 4.3M |
| May 15, 2026 | 0.40 | 0.40 | 0.35 | 0.36 | 627.8K |
| May 14, 2026 | 0.36 | 0.41 | 0.35 | 0.41 | 1.09M |
| May 13, 2026 | 0.32 | 0.37 | 0.32 | 0.36 | 1.66M |
| May 12, 2026 | 0.28 | 0.33 | 0.28 | 0.31 | 1.86M |
| May 11, 2026 | 0.29 | 0.30 | 0.28 | 0.28 | 726.96K |
| May 08, 2026 | 0.33 | 0.33 | 0.29 | 0.29 | 997.87K |
| May 07, 2026 | 0.33 | 0.34 | 0.30 | 0.31 | 677.56K |
| May 06, 2026 | 0.32 | 0.34 | 0.31 | 0.33 | 869.26K |
| May 05, 2026 | 0.34 | 0.34 | 0.31 | 0.32 | 1.34M |
| May 04, 2026 | 0.35 | 0.36 | 0.34 | 0.35 | 791.38K |
| Apr 30, 2026 | 0.33 | 0.35 | 0.32 | 0.35 | 1.47M |
| Apr 29, 2026 | 0.42 | 0.42 | 0.33 | 0.34 | 3.79M |
| Apr 28, 2026 | 0.61 | 0.63 | 0.37 | 0.42 | 15.06M |
| Apr 27, 2026 | 1.41 | 1.43 | 1.38 | 1.42 | 115.17K |
Contact Details
About Company
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Company Information
| Employees | 14 |
| Beta | 2.03 |
| Sales or Revenue | $839.36K |
| 5Y Sales Change% | -0.982% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
1.97+0.24%
argenx SE$808.43REGN-4.26-0.67%
Regeneron Pharmaceuticals, Inc.$634.62UTHR10+1.76%
United Therapeutics Corporation$578.43MDGL7.02+1.36%
Madrigal Pharmaceuticals, Inc.$524.28VRTX1.41+0.32%
Vertex Pharmaceuticals Incorporated$435.93PRAX7.04+2.05%
Praxis Precision Medicines, Inc.$350.60KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83KRYS3.23+1.08%
Krystal Biotech, Inc.$302.68ALNY-1.95-0.66%
Alnylam Pharmaceuticals, Inc.$295.50ASND-7.4-3.00%
Ascendis Pharma A/S$239.65Company Overview
Soligenix, Inc. (NASDAQ:SNGX) closed at $1.02 USD, gaining $0.51 (99.81%) from the previous close of $0.51. The stock is currently mid-range between its 52-week high and low $0.28 and $6.23. With a market capitalization of about $10.56 million, Soligenix, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 1.96 million shares, trading with heavier-than-usual volume. Headquartered in Princeton, NJ, Soligenix, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher J. Schaber, the company employs approximately 14 people and listed since April 04, 1994. Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
Technical Performance
SNGX has shown mixed momentum, gaining 0.73% over the past week and -16.36% over the past quarter, though year-to-date performance is up 2.99%. Short-term trend indicators are bullishly aligned (SMA20 0.83%, SMA50 -10.53%, SMA200 -34.39%). The stock’s 14-day RSI is 45.4 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.54% below its high and over 12.75% above its low. Average 10-day trading volume of 11.66 million shares is significantly above the 3-month average of 1.95 million, indicating heightened recent market interest.
Valuation Metrics
Soligenix, Inc. trades at a P/E ratio of -0.43, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.53 suggesting the stock is closer to book value. The P/FCF stands at -0.45, also below market averages.
Dividend & Fair Value
Soligenix, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.46. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Soligenix, Inc. generated EPS of -$3.66 over the past year. Five-year average earnings growth is 46.71%. Wall Street analysts project EPS growth of 48.16% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.56. Next year's EPS is expected at $9.64. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 1076.47% upside. The low target suggests 1076.47% downside. The mean target is $6.00. This offers 1076.47% upside. Soligenix, Inc. earnings surprise history is a mixed track record. The quarter that ended May 08, 2026, missed forecasts by -6.67%. The prior quarter beat by -218.52%. Over the last six quarters, Apple has recorded several small beats. These include 20.0% in March 21, 2025.
Shareholding & Insider Activity
Soligenix, Inc. has 3.26 million shares outstanding. The public float is 4.28 million shares, elevated short interest at 8.10% of float. This equals 264.29 thousand shares. The short ratio is 0.01 days. Institutional investors hold 9.5% of the float. Insiders own 0.15%. CAVAZZA CLAUDIO holds 54.23 million shares, SIGMA TAU FINANZIARIA SPA has 54.23 million shares and BAM Management LLC has 21.57 million shares.
Financial & Profitability Overview
On valuation metrics, Soligenix trades at a P/E of -0.43, P/S of 0.00 and P/B of 1.53. The current ratio is 1.81 and quick ratio is 1.81. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -144165.95 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.11, supported by a cash flow-to-debt ratio of -32.59.
Quarterly Financial Highlights
The company ended the quarter with $8.45M in cash and short-term investments, a total debt of $3.49M, and net debt of - $4.95M. Total assets were $9.80M, with equity of $2.52M. Financials further reflected weakness, with operating cash flow of - $8.60M, free cash flow of - $8.60M, and capital expenditures of $0.00.
Price Forecast & Outlook
Our AI price prediction model suggests that Soligenix, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -62.96%, with price expected at $0.19 by June 09, 2026, within a range of $0.00 to $0.50 3-Month Outlook: Projected rise of 42.3%, reaching $0.73 by August 24, 2026, with a range of $0.63 to $0.84. 1-Year Outlook: Projected loss of -74.66%, with price at $0.13 by May 26, 2027, within a range of $0.00 to $0.42.
Key Takeaways
Soligenix, Inc. (NASDAQ:SNGX) shares are flat 2.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Soligenix, Inc. trading at a premium to the broader market with a P/E of -0.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.17, suggesting 1102.73% upside. Our AI forecast model points to short-term weakness (-62.96% over two weeks), a medium-term rise (42.3% over three months), and a longer-term loss (-74.66% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Soligenix, Inc. (SNGX) stock price?
Soligenix, Inc. (NASDAQ: SNGX) stock price is $0.94 in the last trading session. During the trading session, SNGX stock reached the peak price of $1.13 while $0.81 was the lowest point it dropped to. The percentage change in SNGX stock occurred in the recent session was 83.27% while the dollar amount for the price change in SNGX stock was $0.43.
SNGX's industry and sector of operation?
The NASDAQ listed SNGX is part of Biotechnology industry that operates in the broader Healthcare sector. Soligenix, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of SNGX?
Mr. Jonathan L. Guarino C.P.A., CGMA
Senior Vice President, Chief Financial Officer & Corporation Sec.
Dr. Richard C. Straube M.D., MSc.
Senior Vice President & Chief Medical Officer
Mr. Richard L. Dunning
Executive Officer
Mr. Jonathan L. Guarino CPA, CGMA
Senior Vice President, Chief Financial Officer & Corporation Sec.
Dr. Oreola Donini Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. Christopher J. Schaber Ph.D.
Chairman of Directors, Chief Executive Officer & Pres
Senior Vice President, Chief Financial Officer & Corporation Sec.
Dr. Richard C. Straube M.D., MSc.
Senior Vice President & Chief Medical Officer
Mr. Richard L. Dunning
Executive Officer
Mr. Jonathan L. Guarino CPA, CGMA
Senior Vice President, Chief Financial Officer & Corporation Sec.
Dr. Oreola Donini Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. Christopher J. Schaber Ph.D.
Chairman of Directors, Chief Executive Officer & Pres
How SNGX did perform over past 52-week?
SNGX's closing price is 83.21% higher than its 52-week low of $0.28 where as its distance from 52-week high of $6.23 is -91.77%.
How many employees does SNGX have?
Number of SNGX employees currently stands at 14.
Link for SNGX official website?
Official Website of SNGX is: https://www.soligenix.com
How do I contact SNGX?
SNGX could be contacted at phone 609 538 8200 and can also be accessed through its website. SNGX operates from 29 Emmons Drive, Princeton, NJ 08540, United States.
How many shares of SNGX are traded daily?
SNGX stock volume for the day was 230.08M shares. The average number of SNGX shares traded daily for last 3 months was 1.96M.
What is the market cap of SNGX currently?
The market value of SNGX currently stands at $9.69M with its latest stock price at $0.94 and 10.31M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep